Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study
23 oct. 2018 07h30 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
05 oct. 2018 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Otonomy to Present at Cantor Fitzgerald Global Healthcare Conference
25 sept. 2018 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Iterum to Present at Cantor Fitzgerald Global Healthcare Conference
25 sept. 2018 16h05 HE
|
Iterum Therapeutics plc
DUBLIN and CHICAGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens,...
Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
18 sept. 2018 08h00 HE
|
Iterum Therapeutics plc
Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead antibiotic product candidate sulopenem Potential to be first and only oral and IV penem antibiotic available...
Naturopathic Doctors Offer Botanical Medicine to Manage Cold and Flu
05 sept. 2018 12h00 HE
|
Institute for Natural Medicine
Seattle, Sept. 05, 2018 (GLOBE NEWSWIRE) -- As new research uncovers that nearly one third of antibiotic prescriptions are not needed and not effective, more people are seeking out non-drug...
Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights
14 août 2018 07h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant...
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
09 août 2018 16h05 HE
|
Iterum Therapeutics plc
First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for uncomplicated urinary tract infections in over...
Otonomy Announces FDA Approval of OTIPRIO(R) for Acute Otitis Externa
02 mars 2018 11h55 HE
|
Otonomy, Inc.
SAN DIEGO, March 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that the...
Otonomy Announces Plan to Focus Resources on Development Programs
27 nov. 2017 16h30 HE
|
Otonomy, Inc.
Company to focus resources on completing OTIVIDEX™ clinical development to support U.S. regulatory approval for Ménière’s disease, and advancing multiple other programs addressing hearing loss and...